Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach

Junjie Jiang, Yongfeng Ding, Jun Lü, Yanyan Chen, Yiran Chen, Wenyi Zhao, Wenfan Chen, Mei Kong, Chengzhi Li, Xiaodong Teng, Quan Zhou, Nong Xu, Donghui Zhou, Zhan Zhou, Haiyong Wang, Lisong TengInternational Journal of Biological Sciences 2022 · DOI

Abstract

Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer (GC) that histologically resembles hepatocellular carcinoma (HCC). Despite its low incidence, HAS had a poor 5-year survival rate. Currently, the linkages between clinicopathological and genomic features of HAS and its therapeutic targets remain largely unknown. Herein, we enrolled 90 HAS patients and 270 stage-matched non-HAS patients from our institution for comparing clinicopathological features. We found that HAS had worse overall survival and were more prone to develop liver metastasis than non-HAS in our cohort, which was validated via meta-analysis. By comparing whole-exome sequencing data of HAS (n=30), non-HAS (n=63), and HCC (n=355, The Cancer Genome Atlas), we identified a genomic landscape associated with unfavorable clinical features in HAS, which contained frequent somatic mutations and widespread copy number variations. Notably, signaling pathways regulating pluripotency of stem cells affected by frequent genomic alterations might contribute to liver metastasis and poor prognosis in HAS patients. Furthermore, HAS developed abundant multiclonal architecture associated with liver metastasis. Encouragingly, target analysis suggested that HAS patients might potentially benefit from anti-ERBB2 or anti-PD-1 therapy. Taken together, this study systematically demonstrated a high risk of liver metastasis and poor prognosis in HAS, provided a clinicogenomic landscape underlying these unfavorable clinical features, and identified potential therapeutic targets, laying the foundations for developing precise diagnosis and therapy in this rare but lethal disease.

Introduction: The "Wolf in Sheep’s Clothing"

Hepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive subtype of gastric cancer, accounting for less than 2% of cases. It is characterized by its histological resemblance to hepatocellular carcinoma (HCC) and frequent production of alpha-fetoprotein (AFP). Due to its rarity, HAS is often misdiagnosed, and standardized treatment protocols are lacking. Patients face a dismal prognosis, with 5-year survival rates as low as 9% in advanced cases. The defining clinical challenge of HAS is its extreme propensity for liver metastasis. This study aims to bridge the knowledge gap by identifying the clinicogenomic drivers behind this lethality and uncovering actionable therapeutic targets.

Histological features of HAS showing resemblance to liver cancer.

Methods and Datasets

The researchers conducted an integrative analysis using a multi-pronged approach:

  • Clinicopathological Comparison: 90 HAS patients from the ZJU cohort (Zhejiang University) were compared against 270 stage-matched non-HAS gastric cancer patients.
  • Genomic Sequencing: Whole-exome sequencing (WES) was performed on tumor-normal pairs from 30 HAS and 63 non-HAS cases.
  • Comparative Genomics: Data from 355 HCC patients (TCGA-LIHC) served as a reference.
  • Bioinformatics: Somatic mutations and copy number variations (CNVs) were analyzed using MutSigCV and GISTIC2.0. Clonal architecture was reconstructed using SciClone, PyClone, and MOBSTER.
  • Validation: Clinical findings were validated using the SEER database and a meta-analysis of five published studies.

Results: A High Risk of Liver Metastasis

The clinical analysis confirmed that HAS patients have significantly worse overall survival (Hazard Ratio = 1.72) and a much higher rate of liver metastasis compared to stage-matched non-HAS patients (41.1% vs. 17.8%).

Comparison of liver metastasis rates and sites between HAS and non-HAS patients.

Genomic Landscape and Stem-like Signaling

The study identified a unique genomic landscape in HAS. While it shares some features with HCC, such as TP53 mutations (66.7%) and MYC amplification, it possesses distinct "hotspots," notably the 17q12 amplification containing ERBB2 (HER2) and CDK12.

A key finding was the enrichment of alterations in signaling pathways regulating the pluripotency of stem cells. Frequent mutations or amplifications in genes like OCT4-pg1, HUWE1, and MYCBP2 suggest that HAS cells adopt a stem-like state, facilitating their migration and colonization of the liver.

Multiclonal Complexity

HAS tumors exhibited significantly higher intratumor heterogeneity than standard gastric cancers. Approximately 69% of HAS tumors were multiclonal, compared to 45.2% of non-HAS cases. This complex multiclonal architecture was directly correlated with the increased risk of liver metastasis.

Therapeutic Opportunities

The study identified two promising avenues for precision medicine:

  1. Anti-ERBB2 Therapy: 33% of HAS patients harbored ERBB2 amplification. A pilot study showed that 100% (3/3) of treated patients experienced a dramatic reduction in tumor markers.
  2. Immunotherapy: HAS tumors showed a higher Tumor Mutational Burden (TMB) than standard gastric cancer. 80% (4/5) of patients treated with anti-PD-1 therapy showed a significant clinical response.

Discussion and Future Directions

While this represents the largest integrative clinicogenomic study of HAS to date, the sample size for sequencing remains limited by the disease's rarity. The retrospective nature of the study also warrants caution. Future research should focus on functional validation of the identified stem cell pathways and prospective clinical trials to confirm the efficacy of HER2-targeted and immunotherapy regimens for this lethal disease.

Summary updated

Abstract

Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer (GC) that histologically resembles hepatocellular carcinoma (HCC). Despite its low incidence, HAS had a poor 5-year survival rate. Currently, the linkages between clinicopathological and genomic features of HAS and its therapeutic targets remain largely unknown. Herein, we enrolled 90 HAS patients and 270 stage-matched non-HAS patients from our institution for comparing clinicopathological features. We found that HAS had worse overall survival and were more prone to develop liver metastasis than non-HAS in our cohort, which was validated via meta-analysis. By comparing whole-exome sequencing data of HAS (n=30), non-HAS (n=63), and HCC (n=355, The Cancer Genome Atlas), we identified a genomic landscape associated with unfavorable clinical features in HAS, which contained frequent somatic mutations and widespread copy number variations. Notably, signaling pathways regulating pluripotency of stem cells affected by frequent genomic alterations might contribute to liver metastasis and poor prognosis in HAS patients. Furthermore, HAS developed abundant multiclonal architecture associated with liver metastasis. Encouragingly, target analysis suggested that HAS patients might potentially benefit from anti-ERBB2 or anti-PD-1 therapy. Taken together, this study systematically demonstrated a high risk of liver metastasis and poor prognosis in HAS, provided a clinicogenomic landscape underlying these unfavorable clinical features, and identified potential therapeutic targets, laying the foundations for developing precise diagnosis and therapy in this rare but lethal disease.
BibTeX
@article{jiang2022integrative,
  author = {Junjie Jiang and Yongfeng Ding and Jun Lü and Yanyan Chen and Yiran Chen and Wenyi Zhao and Wenfan Chen and Mei Kong and Chengzhi Li and Xiaodong Teng and Quan Zhou and Nong Xu and Donghui Zhou and Zhan Zhou and Haiyong Wang and Lisong Teng},
  title = {{Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach}},
  journal = {International Journal of Biological Sciences},
  year = {2022},
  doi = {10.7150/ijbs.71449},
}
Figure